Bridge Realization Estimate
ML model predicts what fraction of the bridge is achievable (accuracy: 60%, n=5,839)
Expected realization: 69% of modeled bridge. Strengths: Occupancy Rate, Net-to-Gross Ratio. Risks: Bed Count, Commercial Payer %. Risk-adjusted uplift: $22.2M (vs $32.4M modeled).
EBITDA Bridge — 7 RCM Levers
Each bar shows the annual EBITDA impact at full run-rate. Revenue levers increase top-line; cost levers reduce operating expense; cash acceleration releases working capital. Calibrated to published research bands (Denial 12%→5% = $8-15M on $400M NPR).
Lever Detail
Each value shows its data source. SELLER = seller data room, DEFAULT = model default, BENCHMARK = P75 peer benchmark.
| Lever | Current | Target | Revenue | Cost | EBITDA | WC | Ramp |
|---|---|---|---|---|---|---|---|
| Cost to Collect | 4.5% DEFAULT | 2.5% BENCHMARK | $0 | $12.3M | $12.3M | $0 | 12mo |
| Denial Rate Reduction | 12.0% DEFAULT | 6.5% BENCHMARK | $11.8M | $338K | $12.2M | $0 | 12mo |
| A/R Days Reduction | 52.00 DEFAULT | 38.00 BENCHMARK | $1.9M | $5.6M | $7.5M | $23.6M | 9mo |
| Clean Claim Rate | 88.0% DEFAULT | 96.0% BENCHMARK | $0 | $394K | $394K | $0 | 6mo |
| Net Collection Rate | 93.5% DEFAULT | 25.7% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
| CDI / Case Mix Index | 135.0% DEFAULT | 142.0% BENCHMARK | $0 | $0 | $0 | $0 | 18mo |
Implementation Timing Curve
Linear ramp to full run-rate per lever. Month 0 = close date. Partners should expect 60-70% of total uplift realized by month 12.
| Lever | M0 | M3 | M6 | M9 | M12 | M18 | M24 | M36 |
|---|---|---|---|---|---|---|---|---|
| Cost to Collect | $0 | $3.1M | $6.1M | $9.2M | $12.3M | $12.3M | $12.3M | $12.3M |
| Denial Rate Reduction | $0 | $3.0M | $6.1M | $9.1M | $12.2M | $12.2M | $12.2M | $12.2M |
| A/R Days Reduction | $0 | $2.5M | $5.0M | $7.5M | $7.5M | $7.5M | $7.5M | $7.5M |
| Clean Claim Rate | $0 | $197K | $394K | $394K | $394K | $394K | $394K | $394K |
| Cumulative | $0 | $8.8M | $17.6M | $26.2M | $32.4M | $32.4M | $32.4M | $32.4M |
Returns Sensitivity (IRR / MOIC)
5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Green = exceeds 20% IRR hurdle. Amber = 15-20%. Red = below hurdle or loss. RCM uplift of $32.4M is added at exit.
| Entry \ Exit | 9.0x | 10.0x | 11.0x | 11.5x | 12.0x |
|---|---|---|---|---|---|
| 8.0x | 47% / 6.8x | 51% / 7.9x | 55% / 9.0x | 57% / 9.6x | 59% / 10.1x |
| 9.0x | 42% / 5.7x | 46% / 6.7x | 50% / 7.7x | 52% / 8.2x | 54% / 8.7x |
| 10.0x | 37% / 4.8x | 42% / 5.7x | 46% / 6.6x | 48% / 7.0x | 49% / 7.5x |
| 11.0x | 32% / 4.0x | 37% / 4.9x | 42% / 5.7x | 43% / 6.1x | 45% / 6.5x |
| 12.0x | 28% / 3.4x | 33% / 4.2x | 38% / 4.9x | 40% / 5.3x | 42% / 5.7x |
Covenant Headroom (at 10x Entry, 6.5x Max Leverage)
Pro forma EBITDA can decline -7% before the 6.5x covenant trips. RCM uplift reduces leverage from 8.5x to 7.0x, adding 1.5 turns of cushion.
5-Year Value Creation Waterfall
EBITDA trajectory: 3% organic growth + RCM uplift ramp (full run-rate at month 18).
| Base EBITDA | RCM Uplift | Total | Margin | |
|---|---|---|---|---|
| Entry | $151.6M | — | $151.6M | 24.6% |
| Year 1 | $156.1M | +$21.6M | $177.7M | 28.9% |
| Year 2 | $160.8M | +$32.4M | $193.1M | 31.4% |
| Year 3 | $165.6M | +$32.4M | $198.0M | 32.2% |
| Year 4 | $170.6M | +$32.4M | $202.9M | 33.0% |
| Year 5 | $175.7M | +$32.4M | $208.0M | 33.8% |
Achievement Sensitivity
What if we only achieve a fraction of each lever? 50% = conservative, 75% = base management case, 100% = plan, 120% = stretch.
| Lever | 50% | 75% | 100% | 120% |
|---|---|---|---|---|
| Cost to Collect | $6.1M | $9.2M | $12.3M | $14.8M |
| Denial Rate Reductio | $6.1M | $9.1M | $12.2M | $14.6M |
| A/R Days Reduction | $3.7M | $5.6M | $7.5M | $9.0M |
| Clean Claim Rate | $197K | $295K | $394K | $472K |
| Total | $16.2M | $24.3M | $32.4M | $38.8M |
Peer Context — Where This Hospital Sits
Key metrics vs 74 size-matched peers. Low percentile on margin/efficiency metrics = more room for improvement = larger bridge opportunity.
| Metric | Hospital | P25 | P50 | P75 | Percentile |
|---|---|---|---|---|---|
| Op Margin | 24.6% | -15.8% | 4.5% | 13.7% | P85 |
| Net-to-Gross | 10.4% | 12.5% | 18.2% | 25.6% | P12 |
| Occupancy | 74.1% | 63.8% | 69.5% | 78.8% | P61 |
| Rev/Bed | $1.2M | $1.1M | $1.3M | $1.7M | P35 |
| Exp/Bed | $895K | $905K | $1.3M | $1.8M | P24 |
Bridge Methodology
Coefficients calibrated to published research bands: denial 12%→5% = $8-15M on $400M NPR. Current metrics estimated from HCRIS public data and ML predictions. Target metrics set at P75 peer benchmarks with 60% gap closure assumption. Revenue levers use NPR × delta × avoidable share. Cost levers use claims volume × cost per reworked claim. Working capital from AR reduction is one-time cash (not included in recurring EBITDA). Returns assume 5.5x leverage, 3% organic growth, 10%/yr debt paydown.